MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by
MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by Boston Scientific, codevelopment responsibilities for integrating Boston Scientific's device platforms with MediGuide's proprietary guidance system, exclusive global distribution, and an option for Boston Scientific to acquire MediGuide at a future time.
The cornerstone of the alliance is an advanced navigation system developed by the Arlington, VA, company. The Medical Positioning System (MPS) enables real-time tracking of miniature sensors integrated into therapeutic and diagnostic medical devices. These devices register their exact location and orientation utilizing advanced diagnostic systems such as Boston Scientific's intravascular ultrasound system, as well as other diagnostic systems including x-ray angiography, MR, and CT. Boston Scientific and MediGuide plan to integrate the MPS with Boston Scientific's IVUS.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.